Pharmaceutical companies Elan and Biogen say a late-stage clinical trial of their multiple sclerosis drug Tysabri has achieved its objective.
The companies said the trial achieved its main aim of slowing the progression of disability in patients with relapsing forms of MS.
They said Tysabri treatment led to a 42% reduction in the risk of disability progression compared with a placebo.
Elan shares were up 61 to €21.66 on the ISEQ this lunchtime.
